

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
09/995,010	11/27/2001	Stanislaw R. Burzynski	BURG:04910379.0049.NPUS00 9045		
75	90 01/29/2004	EXAMINER			
HOWREY SI	MON ARNOLD & '	JONES, DWAYNE C			
750 Bering Driv Houston, TX			ART UNIT	PAPER NUMBER	
, <u>-</u>		·	1614		
		DATE MAILED: 01/29/2004			

Please find below and/or attached an Office communication concerning this application or proceeding.

			Applicatio	lication No. Applicant(s		(s)			
Office Action Summary			09/995,01	0	BURZYNSKI, STANISLAW R.				
			Examiner		Art Unit				
			Dwayne C		1614				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply									
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status									
1)⊠	Responsive to communication(s) filed on 12 November 2003.								
2a) <u></u> ☐	This action is FINAL . 2b) This action is non-final.								
3)	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Disposition of Claims									
4)🛛	4)⊠ Claim(s) <u>14-20,22-25,29 and 31</u> is/are pending in the application.								
4a) Of the above claim(s) is/are withdrawn from consideration.									
5) Claim(s) is/are allowed.									
6)⊠ Claim(s) <u>14-20 and 22-25</u> is/are rejected.									
· <u> </u>	7)⊠ Claim(s) <u>29 and 31</u> is/are objected to.								
8) Claim(s) are subject to restriction and/or election requirement.									
Application Papers									
9) The specification is objected to by the Examiner.									
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.									
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.									
Priority under 35 U.S.C. §§ 119 and 120									
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).									
a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received.									
	2. Certified copies of the priority documents have been received in Application No								
	3. Copies of the certified copies of the priority documents have been received in this National Stage								
application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.									
13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application)									
since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.									
a) ☐ The translation of the foreign language provisional application has been received.									
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.									
Attach	t/a)								
Attachmen	t(s) e of References Cited (PTO-892)			4) Interview Summary	(PTO-413) Paper No	(e)			
2) Notic	e of Draftsperson's Patent Drawing Review (PTC			5) Notice of Informal Pa					
3) 🔲 Inform	mation Disclosure Statement(s) (PTO-1449) Pap	er No(s)	<u>·</u> ·	6) Other: .					

Application/Control Number: 09/995,010 Page 2

Art Unit: 1614

DETAILED ACTION

Status of Claims

- 1. Claims 14-20, 22-25, 29, and 31 are pending.
- 2. Claims 14-20, 22-25 are rejected.
- 3. Claims 1-13, 21, 26-28, and 30 are cancelled as per the amendment of November 12, 2003.
- 4. Claims 29 and 31 are objected.

Response to Arguments

5. Applicant's arguments with respect to claims 14-20, 22-25, 29, and 31 are have been considered but are most in view of the new ground(s) of rejection.

Claim Objections

6. Claims 29 and 31 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Claim Rejections - 35 USC § 103

- 7. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 09/995,010 Page 3

Art Unit: 1614

8. The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 9. Claims 14-20, and 22-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Jaeger of U.S. Patent No. 4,826,680. Jaeger teaches of a pharmaceutical composition that contains riboflavin and the amino acids of glycine, alanine, serine, threonine, valine, and arginine, (see claims 1 and 4). In addition, Jaeger disclose that this composition has excellent immunological properties, and is useful in the treatment of cancer, (see column 1). Jaeger also teach that this composition contains suitable pharmaceutical additives and carriers, (seé column 3, lines 54-62). The instant claims are directed to composition claims with an intended use of a composition consisting of riboflavin, arginine, and alanine, glycine, serine, threonine, and valine. The prior art reference of Jaeger also teach of a composition that contains the very same components that are instantly claimed. The only distinction between the prior composition and the instant invention lies with the transitional language of the phrase "consisting of " in the instant application and "comprising" claim language as disclosed by Jaeger. Even though the instant composition employs the use of the "consisting" claim language, the prior art reference of Jaeger specifically

Application/Control Number: 09/995,010 Page 4

Art Unit: 1614

teach and provide motivation to use riboflavin in the presence of , arginine, and alanine, glycine, serine, threonine, and valine in order to make pharmaceutical preparations.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. C. Jones whose telephone number is (703) 308-4634 until about February 6, 2004 and then changes to (571) 272-0578. The examiner can normally be reached on Mondays through Fridays from 8:30 am to 6:00 pm. The examiner can also be reached on alternate Mondays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on (703) 308-4725 until about February 6, 2004 and then changes to (571) 272-0584. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-

1235.

MARY EXAMINER
Tech. Ctr. 1614